03/01/21 8:00 AMNYSE : LCTXLineage Cell Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 11, 2021 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2020 financial and operating results on Thursday, March 11, 2021,RHEA-AIneutral
02/23/21 8:00 AMNYSE : LCTXLineage to Present at the Raymond James 42nd Annual Institutional Investors Conference on March 1, 2021 and the H.C. Wainwright Global Life Sciences Conference on March 9, 2021Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 42 nd Annual InstitutionalRHEA-AIneutral
02/16/21 8:00 AMNYSE : LCTXLineage to Host Virtual OPC1 Investor & Analyst Day on February 22, 2021Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced it will be hosting a virtual Investor and Analyst Day on February 22, 2021 at 1:30pm PT / 4:30pm ET to discuss theRHEA-AIneutral
02/08/21 8:00 AMNYSE : LCTXLineage Enters Into Exclusive Agreement with Neurgain Technologies to Evaluate Novel Delivery System for OPC1 to Treat Spinal Cord InjuryLineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has entered into an exclusive option and license agreement with Neurgain Technologies, Inc. ("Neurgain"), aRHEA-AIpositive
01/21/21 8:00 AMNYSE : LCTXLineage Posts Series of Webinars Highlighting Recent Progress With its Three Clinical-Stage Allogeneic Cell Transplant Programs Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies to address unmet medical needs, recently highlighted to members of the investment community its clinical and operational progress through a series of webinarsRHEA-AIneutral
01/20/21 4:18 PMNYSE : LCTXLineage Cell Therapeutics Announces Change to Executive Team Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brandi Roberts, Chief Financial Officer, provided notice of her resignation on January 15 th, 2021, in order toRHEA-AIneutral
12/28/20 8:00 AMNYSE : LCTXLineage Cell Therapeutics Provides End of Year Shareholder Letter Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today provided a year-end review and an outline of its plans for 2021.To Our Shareholders,As we reach the end of an eventful 2020,RHEA-AIpositive
